Vice President, Patient Operations
Beam Therapeutics
Summary
Beam is looking for a highly motivated, strategic, and collaborative leader to join our growing Commercial team. The VP, Patient Operations, will shape the strategy, build and oversee the execution of patient scheduling and apheresis operations, including leading the selection and implementation of a cell therapy orchestration platform. The focus in the short- to mid-term will be on risto-cel, an ex vivo autologous hematopoietic stem cell-based gene therapy for the treatment of severe sickle cell disease (SCD). Patient Operations will be critical for the provider and patient experience and as such, this role will be a crucial member of the cross-functional team preparing for Beam's potential first product commercialization. Additionally, this position will be a key strategic thought partner defining how to commercialize Beam's next-generation hematology programs, which have the potential to address significantly more patients. The successful candidate will also help shape the strategy for commercial patient supply for our in vivo genetic medicines products.
Job description
Position Overview
Beam is looking for a highly motivated, strategic, and collaborative leader to join our growing Commercial team. The VP, Patient Operations, will shape the strategy, build and oversee the execution of patient scheduling and apheresis operations, including leading the selection and implementation of a cell therapy orchestration platform. The focus in the short- to mid-term will be on risto-cel, an ex vivo autologous hematopoietic stem cell-based gene therapy for the treatment of severe sickle cell disease (SCD). Patient Operations will be critical for the provider and patient experience and as such, this role will be a crucial member of the cross-functional team preparing for Beam's potential first product commercialization. Additionally, this position will be a key strategic thought partner defining how to commercialize Beam's next-generation hematology programs, which have the potential to address significantly more patients. The successful candidate will also help shape the strategy for commercial patient supply for our in vivo genetic medicines products.
Responsibilities
- Define strategy for Patient Operations, including patient scheduling rules, manufacturing slot allocation, and exception management.
- Partner with Manufacturing, Supply Chain, Quality, Regulatory, IT and others to ensure scalable processes for patient scheduling and apheresis operations that meet both Beam's business needs and ensure an exceptional patient and provider treatment experience.
- Provide strategic and operational leadership regarding the implementation of a cell therapy orchestration platform and integration into other systems to enable functions such as patient registration and scheduling, chain of identity / chain of custody (COI/COC) traceability, order management, inbound and outbound cell logistics etc.
- Partner with Key Account Management to define organizational needs to onboard and support apheresis operations at treatment centers.
- Build and manage teams to execute patient scheduling and apheresis operations.
Qualifications
- BS/BA in a relevant academic field; MBA, MD, PhD, or other graduate degree strongly preferred with 12+ years experience within the pharma/biotech/biopharma space in roles of progressively increasing responsibility.
- Experience in gene and/or cell therapy strongly desired, particularly in autologous cell therapy.
- Sophisticated understanding of the operational complexity and evolving scientific, clinical, regulatory, competitive, and economic trends in the cell / gene therapy industry, and able to adapt operational strategies accordingly.
- Proven track record in cross-functional leadership role or other cross-disciplinary background with successful team leadership experience required.
- Exceptional interpersonal skills and collaborative nature with strong ability to influence, motivate, inspire, encourage and develop others.
- Driven by patient needs and comfortable operating in a highly complex and technical environment while dealing with ambiguity.
- Experience with U.S. commercialization.
- Experience in both large and small company environments a plus.
- Role is based in Cambridge, MA, or hybrid. East coast preferred.
- Ability to travel 25% as needed.
Requirements
- BS/BA in a relevant academic field
- MBA, MD, PhD, or other graduate degree strongly preferred
- 12+ years experience within the pharma/biotech/biopharma space in roles of progressively increasing responsibility
- Experience in gene and/or cell therapy strongly desired, particularly in autologous cell therapy
- Sophisticated understanding of operational complexity and evolving scientific, clinical, regulatory, competitive, and economic trends in the cell / gene therapy industry
- Proven track record in cross-functional leadership role or other cross-disciplinary background with successful team leadership experience required
- Exceptional interpersonal skills and collaborative nature with strong ability to influence, motivate, inspire, encourage and develop others
- Driven by patient needs and comfortable operating in a highly complex and technical environment while dealing with ambiguity
- Experience with U.S. commercialization
- Experience in both large and small company environments a plus
- Ability to travel 25% as needed
Company overview
Beam Therapeutics is a pioneering biotechnology company focused on developing precision genetic medicines through base editing technology. Founded by leading CRISPR researchers, the company leverages its proprietary base editing platform to create therapies that can make precise, single-letter changes to DNA without causing double-strand breaks. Beam's innovative approach addresses genetic diseases at their source by correcting point mutations that cause various inherited disorders. The company's pipeline includes programs targeting sickle cell disease, beta-thalassemia, and other genetic conditions. Beam Therapeutics represents the next generation of gene editing companies, building upon CRISPR technology to enable more precise and potentially safer genetic modifications. The company has established strategic partnerships and collaborations to advance its therapeutic programs and expand the applications of its base editing technology across multiple disease areas.